Genetic Association Of Excision Repair Cross Complementation Group (Ercc Rs3212986) Polymorphism With Oscc.

Authors

  • Prithiksha. N
  • Karthikeyan Murthykumar
  • Vijayashree Priyadharshini
  • Dhanraj Ganapathy
  • Marina

Keywords:

Alleles, Oral squamous cell carcinoma, ERCC, Polymorphism

Abstract

Background Introduction: Oral squamous cell carcinoma (OSCC) is the leading cause of cancer morbidity and mortality . Despite new advances in the diagnosis and therapeutic approaches, the 5-year survival remains low. While relapse of OSCC remains a major clinical challenge, the incidence of relapse among patients varies,even for those with a similar stage of disease at diagnosis or those who undergo the same treatment . This implies that other factors, such as genetic variations, may play an important role in disease prognosis

Aim:The aim of the present study was to analyze the association between ERCC1 (rs3212986) gene polymorphism and OSCC .

Materials and Methods: A total of 100 participants were recruited for this study, which included 50 OSCC patients and 50 healthy controls. Genomic DNA was extracted from the whole blood collected from the participants. DNA was amplified using specific primers flanking the region of ERCC1 (rs3212986) gene. The amplicon was further subjected to genotyping using restriction fragment length polymorphism (RFLP) using PvuII enzyme. The genotype obtained based on the RFLP pattern was recorded and used for statistical analysis. The distribution of genotypes and allele frequencies in the OSCC and control groups was compared using the Chi-square test.

Results: The gene frequency and allele frequency were found to be similar in both groups.

Conclusion: The present study denotes that the ERCC1 (rs3212986) polymorphism is not associated with OSCC in the study group analyzed.

Downloads

Download data is not yet available.

References

[1 Senghore T, Chien HT, Wang WC, Chen YX, Young CK, Huang SF, et al. Polymorphisms in ERCC5 rs17655 and ERCC1 rs735482 Genes Associated with the Survival of Male Patients with Postoperative Oral Squamous Cell Carcinoma Treated with Adjuvant Concurrent Chemoradiotherapy [Internet]. Vol. 8, Journal of Clinical Medicine. 2019. p. 33. Available from: http://dx.doi.org/10.3390/jcm8010033

2. Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, et al. Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study. Cancer. 2013 Dec 15;119(24):4242–8.

3. Leemans CR, Tiwari R, Nauta JJP, Van Der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor [Internet]. Vol. 73, Cancer. 1994. p. 187–90. Available from: http://dx.doi.org/10.1002/1097-0142(19940101)73:1<187::aid-cncr2820730132>3.0.co;2-j

4. Markopoulos AK. Current Aspects on Oral Squamous Cell Carcinoma [Internet]. Vol. 6, The Open Dentistry Journal. 2012. p. 126–30. Available from: http://dx.doi.org/10.2174/1874210601206010126

5. Zhang BB, Wang DG, Xuan C, Sun GL, Deng KF. Genetic 135G/C polymorphism of RAD51 gene and risk of cancer: a meta-analysis of 28,956 cases and 28,372 controls [Internet]. Vol. 13, Familial Cancer. 2014. p. 515–26. Available from: http://dx.doi.org/10.1007/s10689-014-9729-0

6. Sekaran S, Selvaraj V, Ganapathy D, Rajamani Sekar SK. Can surgery induce cancer recurrence or metastasis? Revisiting the relationship between anesthetic selection and outcomes in cancer surgery. Int J Surg. 2023 Sep 1;109(9):2878–9.

7. Ganapathy D, Sekaran S, Pitchaiah S. Is prognostic monitoring of high-risk populations at risk for oral cancer necessary after infection with COVID-19? Oral Oncol. 2022 Aug;131:105968.

8. Sekar D, Murthykumar K, Ganapathy D. miR-206 and its mimics: A predictive biomarker and therapeutic molecule in the treatment of oral cancer. Oral Oncol. 2022 May;128:105849.

9. Sekaran S, Royapuram Parathasarathy P, Palati S, Ganapathy D, Muzammil K, Nasir N. Commentary: Telemedicine for cancer patients in the COVIDian era—A long overdue promise? Frontiers in Public Health [Internet]. 2022;10. Available from: https://www.frontiersin.org/articles/10.3389/fpubh.2022.931380

10. Otsuru M, Ota Y, Aoki T, Yamazaki H, Arai T, Suzuki T, et al. A study of adjuvant chemoradiotherapy with tri-weekly cisplatin for post-operative high-risk squamous cell carcinoma of oral cavity [Internet]. Vol. 25, Journal of Japan Society for Oral Tumors. 2013. p. 1–6. Available from: http://dx.doi.org/10.5843/jsot.25.1

11. Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017 [Internet]. Vol. 15, Journal of the National Comprehensive Cancer Network. 2017. p. 761–70. Available from: http://dx.doi.org/10.6004/jnccn.2017.0101

12. Liu H, Qi B, Guo X, Tang LQ, Chen QY, Zhang L, et al. Genetic variations in radiation and chemotherapy drug action pathways and survival in locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. PLoS One. 2013 Dec 10;8(12):e82750.

13. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945–52.

14. Jin H, Xie X, Wang H, Hu J, Liu F, Liu Z, et al. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma. PLoS One. 2014 Jul 15;9(7):e101256.

15. Leeman JE, Li JG, Pei X, Venigalla P, Zumsteg ZS, Katsoulakis E, et al. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques [Internet]. Vol. 3, JAMA Oncology. 2017. p. 1487. Available from: http://dx.doi.org/10.1001/jamaoncol.2017.0973

16. Rouillon C, White MF. The evolution and mechanisms of nucleotide excision repair proteins [Internet]. Vol. 162, Research in Microbiology. 2011. p. 19–26. Available from: http://dx.doi.org/10.1016/j.resmic.2010.09.003

17. Nanda SS, Gandhi AK, Rastogi M, Khurana R, Hadi R, Sahni K, et al. Evaluation of XRCC1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiation Therapy [Internet]. Vol. 101, International Journal of Radiation Oncology*Biology*Physics. 2018. p. 593–601. Available from: http://dx.doi.org/10.1016/j.ijrobp.2018.03.039

18. Lopes-Aguiar L, Costa EFD, Nogueira GAS, Lima TRP, Visacri MB, Pincinato EC, et al. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation [Internet]. Vol. 8, Oncotarget. 2017. p. 16190–201. Available from: http://dx.doi.org/10.18632/oncotarget.7668

19. Gao C, Wang J, Li C, Zhang W, Liu G. A Functional Polymorphism (rs10817938) in the XPA Promoter Region Is Associated with Poor Prognosis of Oral Squamous Cell Carcinoma in a Chinese Han Population [Internet]. Vol. 11, PLOS ONE. 2016. p. e0160801. Available from: http://dx.doi.org/10.1371/journal.pone.0160801

20. Zhang R, Zhou F, Cheng L, Yu A, Zhu M, Wang M, et al. Genetic variants in nucleotide excision repair pathway predict survival of esophageal squamous cell cancer patients receiving platinum‐based chemotherapy [Internet]. Vol. 57, Molecular Carcinogenesis. 2018. p. 1553–65. Available from: http://dx.doi.org/10.1002/mc.22877

21. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983–91.

22. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005 Mar;127(3):978–83.

23. Yin J, Vogel U, Guo L, Ma Y, Wang H. Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population. Cancer Genet Cytogenet. 2006 Jan 1;164(1):66–70.

24. Tejasvi MLA, Maragathavalli G, Putcha UK, Ramakrishna M, Vijayaraghavan R, Avinash CKA. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. Indian J Pathol Microbiol. 2020 Oct 1;63(4):538.

25. Urun Y, Leow JJ, Fay AP, Albiges L, Choueiri TK, Bellmunt J. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Dec;120:120–6.

Downloads

Published

2023-01-20

How to Cite

1.
N P, Murthykumar K, Priyadharshini V, Ganapathy D, Marina M. Genetic Association Of Excision Repair Cross Complementation Group (Ercc Rs3212986) Polymorphism With Oscc. J Neonatal Surg [Internet]. 2023 Jan. 20 [cited 2026 Jun. 30];12(1):83-9. Available from: https://jneonatalsurg.com/index.php/jns/article/view/10355

Issue

Vol. 12 (2023): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.